Skip to main
LLY

Eli Lilly (LLY) Stock Forecast & Price Target

Eli Lilly (LLY) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 41%
Buy 41%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Eli Lilly and Co demonstrated robust financial performance in 2Q25, surpassing revenue and earnings expectations while also raising full-year guidance. Notably, sales of Mounjaro outside the U.S. surged by 60% quarter-over-quarter, indicating strong growth potential in international markets alongside anticipated improvements in their obesity treatment options. The positive outlook is further supported by projected sales growth of 20.5% for 2026 and exceptional earnings per share growth of 41%, underscoring the company’s strong position in the pharmaceutical market.

Bears say

Eli Lilly and Co faces several substantial risks that negatively impact its stock outlook, including increasing pricing and rebate pressures, and a disappointing trajectory for its tirzepatide product, Mounjaro, which has failed to demonstrate expected cardiac outcome benefits. Additionally, the forecast for orforglipron has been reduced significantly, reflecting growing competitive threats in the cardiometabolic space and a decline in sales expectations, particularly for Zepbound and Mounjaro in the coming quarters. The cumulative effect of these factors raises concerns about Lilly's overall revenue growth potential moving forward.

Eli Lilly (LLY) has been analyzed by 17 analysts, with a consensus rating of Buy. 41% of analysts recommend a Strong Buy, 41% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eli Lilly (LLY) Forecast

Analysts have given Eli Lilly (LLY) a Buy based on their latest research and market trends.

According to 17 analysts, Eli Lilly (LLY) has a Buy consensus rating as of Jan 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1,109.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1,109.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eli Lilly (LLY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.